Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
Chung-Han LeeMartin H VossMaria Isabel CarloYing-Bei ChenMark ZuckerAndrea KnezevicRobert A LefkowitzNatalie ShapnikChloe DadounEd ReznikNeil J ShahColette Ngozi OwensDeaglan Joseph McHughDavid Henry AggenAndrew Leonard LaccettiRitesh R KotechaDarren R FeldmanRobert J MotzerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Cabozantinib plus nivolumab showed promising efficacy in most non-clear-cell RCC variants tested in this trial, particularly those with prominent papillary features, whereas treatment effects were limited in chromophobe RCC. Genomic findings in non-clear-cell RCC variants warrant further study as predictors of response.